Ascent Wealth Partners 13F: New $11M Stake in Eli Lilly and (LLY)

Ascent Wealth Partners picked up a new stake in Eli Lilly and Company LLY, acquiring 9,135 shares valued at roughly $10.6 million. The fund revealed the transaction in a Form 13F filing with the U.S. Securities and Exchange Commission on October 23, 2026. Because this was a brand-new holding for the firm, it represents a fresh entry into the pharmaceutical giant during the period.

LLY Eli Lilly and Company

$1,273.46 ▲ +18.44% year to date

1M 3M YTD

Daily close · Oct 23, 2026

What Changed in Ascent Wealth Partners's Eli Lilly and Company Position

The newly opened position consists of 9,135 shares with a reported market value of $10,570,131 based on the filing date. Since the fund held zero shares previously, this initiation establishes a direct exposure to the drug maker.

Other Institutional Activity in Eli Lilly and Company

Other institutional investors adjusted their holdings around the same time. Wilmington Savings Fund Society, FSB reduced its holdings by 2,600 shares, ending with 25,292 shares worth about $29.3 million. NTV Asset Management boosted its stake by 611 shares, or about 2.0%, to hold 31,222 shares valued at approximately $36.1 million. Lilly Endowment, Inc trimmed its massive holding by 307,272 shares, leaving it with 90,066,978 shares worth about $114.7 billion. Meanwhile, PNC Financial Services Group, Inc. lowered its position by 5,133 shares to finish with 51,322,720 shares valued near $65.4 million.

Eli Lilly and Company Stock Up 0.2%

Eli Lilly and Company shares recently traded around $1,273.57 as of October 24, close to the $1,273.46 level recorded at the close on October 23. The stock sits well above its 50-day moving average of $1,185.32 and comfortably above its 200-day moving average of $1,084.11. The share price remains about 3.6% below its 52-week high of $1,321.21 while resting well above its 52-week low of $806.02.

Recent Earnings

Eli Lilly and Company reported trailing-twelve-month revenue of $79.67 billion alongside earnings of $29.79 per share. The company posted a net profit margin of 33.5% and a return on equity of 102.3%. Revenue grew 47.7% over the prior year. The next earnings report is scheduled for October 29, 2026.

Dividend

The company pays an annual dividend rate of $6.92 per share, which translates to a dividend yield of 0.53%. The payout ratio stands at 21.7% of earnings.

Insider Buying and Selling at Eli Lilly and Company

Company insiders executed several transactions during August 2026 prior to the filing. General Counsel Anat Hakim sold 5,000 shares on August 7 at $1,190.00 per share for a total value of $5,950,000. Officer Donald A Zakrowski disposed of 2,000 shares on August 10 at $1785.01—noted as $1185.01 in filings—totaling $2,370,020. Officer Patrik Jonsson parted with 6,500 shares on August 17 at $1,175.10 per share, realizing $7,638,150. None of these transactions were reported as executed under automated Rule 10b5-1 plans.

Analysts Set New Price Targets

Wall Street firms remain largely positive on the outlook for Eli Lilly and Company. JP Morgan maintained an Overweight rating on September 28 while lifting its price target to $1,500.00 from $1,400.00. Morgan Stanley kept an Overweight rating on October 7 with a target moved to $1,430.00 from $1,419.00. Cantor Fitzgerald maintained an Overweight rating on October 8 with a target raised to $1,440.00 from $1,410.00. RBC Capital reiterated an Outperform rating on October 12 holding its target steady at $1,500.00, and Leerink Partners kept an Outperform rating on October 21 while ticking its target up to $1,316.00 from $1,309.00. Overall, the stock carries a consensus buy recommendation from 30 analysts with a mean price target of $1,331.55.

About Eli Lilly and Company

Headquartered in Indianapolis, Indiana, Eli Lilly and Company discovers, develops, and markets human pharmaceutical products worldwide. The healthcare giant focuses on medications addressing major conditions including diabetes, oncology, and immunology, supporting its large market capitalization of roughly $1.17 trillion.

Bottom Line

Ascent Wealth Partners chose to open a new position worth over $10 million in Eli Lilly and Company. Investors will look toward the upcoming earnings release on October 29, 2026, for fresh updates on product sales and profit margins.